NASDAQ · PIIIW

P3 Health Partners Inc.

$0.01 -$0.01 (-42.97%) 1D Market open

Key Metrics

$42.05K
Market cap
P/E · TTM
$1.47B
Revenue · TTM
−$126.25M
Net income
EPS · TTM $-38.73
Dividend yield
Free cash flow
Beta · 1Y -0.48
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 1
    The stock moved +64.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 1
  • Jun 30
    From its May 15 high, the share price fell 86%.

    Peak close $0.07 on May 15; trough close $0.01 on Jun 30. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -86%
  • May 15
    The stock moved +1465.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 15

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value$285.55M
Shares outstanding
52-wk range$0.00 – $0.25
Avg volume · 20D97.7K
Net cash −$285.51M
Book value / share$-44.03
IndustryServices-Health Services
ExchangeNASDAQ
About P3 Health Partners Inc.
IPO dateDec 6, 2021
Employees320

P3 Health Partners Inc is a patient-centered and physician-led population health management company.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.00
P/FCF
EV/EBITDA
EV/Sales0.19
Graham №

Profitability

Gross
Operating -15.2%
Net -8.6%
FCF
ROE / ROIC 17,806.1% · -152.2%

Financial Health

Current ratio0.33
Quick ratio
Debt / equity-2.17
Debt / EBITDA
Net cash −$285.51M
Working capital−$353.28M

Cash Flow · TTM

Operating CF −$85.24M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

-0.9
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings